合并主动脉瓣反流患者经导管主动脉瓣置换术的结局
该观察性研究基于2012年11月至2022年4月的机构TAVR数据库,比较单纯主动脉瓣狭窄(AS)与AS合并中度及以上主动脉瓣反流(AR)患者的TAVR结局。在3295例患者中,605例(53.4%)为严重AS无AR,529例(46.6%)为严重AS合并中度或重度AR;两组在院内死亡率、住院时间、卒中、心肌梗死、永久起搏器需求、输血需求、血管并发症及30天再入院方面均无显著差异(P > .05),生存估计可比,混合瓣膜病与死亡风险增加无关(HR 1.01;95%CI 0.81-1.25;P = .962)。结论认为TAVR可安全用于混合瓣膜病患者,结局与单纯AS相当。
要点
- TAVR可用于混合性主动脉瓣疾病患者,结局与单纯AS相当。
- 两组院内死亡率、卒中、血管并发症及30天再入院无显著差异(P > .05)。
- 混合瓣膜病与死亡风险增加无关(HR 1.01;95%CI 0.81-1.25;P = .962)。
核心结论
- TAVR可安全用于混合瓣膜病患者,结局与单纯AS患者相当。
研究设计与样本
- 观察性研究,使用2012年11月至2022年4月的机构TAVR数据库。
- 比较单纯AS与AS合并中度及以上AR(排除微量或轻度AR)患者的TAVR结局,终点依据VARC-3标准。
主要发现
- 在3295例患者中,605例(53.4%)为严重AS无AR,529例(46.6%)为严重AS合并中度或重度AR。
- 两组院内死亡率、住院时间、卒中、心肌梗死、永久起搏器需求、输血需求、轻微或主要血管并发症及30天再入院均无显著差异(P > .05)。
- 两组瓣环夹层或破裂、冠状动脉阻塞及装置栓塞均无显著差异。
- 两组30天和1年平均压差及瓣周漏率相似,生存估计可比,心力衰竭再入院累积发生率估计可比。
- 多变量Cox回归显示,混合性主动脉瓣疾病与单纯AS相比未增加死亡风险(HR 1.01;95%CI 0.81-1.25;P = .962)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study sought to evaluate outcomes of transcatheter aortic valve replacement (TAVR) in patients with moderate or greater aortic regurgitation (AR). METHODS: This was an observational study using an institutional database of TAVRs from November 2012 to April 2022. The study compared outcomes of TAVR in patients with isolated aortic stenosis (AS) vs patients with AS and concomitant AR (moderate or greater). Those patients with trace or mild AR were excluded. Clinical and echocardiographic outcomes were compared, with end points established by the Valve Academic Research Consortium 3. Kaplan-Meier survival estimation and Cox regression for mortality were performed. Competing-risk cumulative incidence estimates for heart failure readmissions were also compared. RESULTS: Of 3295 patients, 605 (53.4%) had severe AS with no AR and 529 (46.6%) had severe AS with moderate or severe AR. There were no significant differences in in-hospital mortality, length of stay, stroke, myocardial infarction, permanent pacemaker requirement, transfusion requirement, minor or major vascular complications, or 30-day readmissions between the 2 groups (P > .05). There were also no significant differences in annular dissection or rupture, coronary obstruction, or device embolization. Mean gradient and paravalvular leak rates at 30 days and 1 year were similar between the groups. Survival estimates were comparable, and, on multivariable Cox regression, mixed aortic valvular disease was not associated with an increased hazard of death as compared with isolated AS (hazard ratio, 1.01; 95% CI, 0.81-1.25; P = .962). Cumulative incidence estimates for heart failure readmissions were comparable between groups. CONCLUSIONS: TAVR can be safely performed in patients with mixed valvular disease, with outcomes comparable to those in isolated AS.
引用
- Yousef S, Bianco V, Kliner D, et al. Outcomes of Transcatheter Aortic Valve Replacement in Patients With Concomitant Aortic Regurgitation. Ann Thorac Surg. 2023. PMID: 36791833. doi:10.1016/j.athoracsur.2023.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。